Explore 3 Stock Ideas & Industry Insights Download Free Report

Galectin Therapeutics Inc

Company price
3.05 USD -0.09 ( 2.87%)
Last update at 2026-11-13T21:26:00Z
VOLUME
181191
Market Cap
376.17M

Momentum Score

…

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.93
Low
3.31
High
52 Week Price Range
2.03
Low
7.13
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Galectin Therapeutics is a clinical-stage biopharmaceutical company developing therapies that inhibit galectin-3 to address fibrotic and inflammatory diseases. Long-term growth may be supported by advancing its lead galectin-3 inhibitor through development, pursuing partnerships or licensing, and expanding into additional fibrotic indications, which could appeal to investors seeking targeted antifibrotic exposure.
Principal risks include clinical and regulatory failure, lack of commercial revenues creating financing and dilution pressure, and competition from other antifibrotic and NASH programs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.14
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-1.06
ROE
-3727.95%
Net Debt
116.02M
ROCE
-204.37%
Diluted EPS TTM
-0.43

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -30.84M -47.05M -41.07M -38.78M -30.53M
Net income -30.84M -47.05M -41.07M -39.20M -30.98M
Selling general administrative 5.79M 5.86M 5.90M 6.62M 6.36M
Selling and marketing expenses - - 0.04M - -
Gross profit - -0.04M -0.03M - -
Reconciled depreciation 0.05M 0.04M 0.03M 0.03M 0.04M
Ebit -23.51M -41.51M -38.27M -38.35M -30.18M
Ebitda -23.45M -41.47M -38.24M -38.30M -30.18M
Depreciation and amortization 0.05M 0.04M 0.03M 0.05M 0.00M
Operating income -20.09M -42.43M -38.07M -38.35M -30.18M
Other operating expenses 20.09M 42.43M 38.07M 38.35M 30.18M
Interest expense 7.33M 5.54M 2.79M 1.03M 0.49M
Interest income 0.13M 0.34M 0.19M 0.05M 0.00M
Net interest income -7.20M -5.20M -2.07M -0.98M -0.49M
Income tax expense - - -2.99M 0.42M 0.45M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 20.09M 42.40M 38.04M 38.35M 30.18M
Cost of revenue - 0.04M 0.03M - -
Total other income expense net -10.75M -4.61M -2.99M -0.42M -0.35M
Net income from continuing ops -30.84M -47.05M -41.70M -38.78M -30.53M
Net income applicable to common shares - - - -38.87M -30.70M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 19.53M 17.50M 28.20M 21.29M 41.83M
Other current assets 1.72M 2.13M 2.05M 1.96M 2.17M
Total liab 145.73M 120.56M 88.44M 55.20M 40.93M
Total stockholder equity -126.19M -103.07M -60.24M -33.92M 0.89M
Other current liab 4.76M 8.62M 9.14M 9.08M 7.22M
Common stock 0.07M 0.06M 0.06M 0.06M 0.06M
Capital stock 2.28M 2.29M 2.28M 2.29M 2.31M
Retained earnings -432.55M -401.57M -354.37M -309.57M -270.69M
Other liab - - - 0.07M -
Other assets - - 0.00M 0.73M -
Cash 17.72M 15.12M 25.66M 18.59M 39.65M
Total current liabilities 8.03M 35.41M 15.68M 13.01M 9.03M
Current deferred revenue - -6.68M 0.06M - -
Net debt 116.02M 91.12M 46.15M 21.28M -10.59M
Short term debt 0.02M 21.14M 0.05M 0.04M 0.01M
Short long term debt - 21.12M - - -
Short long term debt total 133.74M 106.25M 71.81M 39.87M 29.06M
Other stockholder equity 304.07M 296.22M 293.57M 273.87M 269.81M
Property plant equipment - - - - 0.01M
Total current assets 19.44M 17.25M 27.71M 20.55M 41.82M
Net tangible assets - - - -34.43M 0.37M
Long term debt 133.74M 85.11M 71.74M 39.83M 29.05M
Accounts payable 3.25M 5.66M 6.43M 3.89M 1.80M
Accumulated other comprehensive income - - -1.72M - -
Non currrent assets other 0.10M 0.24M 0.44M 0.73M 0.01M
Non current assets total 0.10M 0.24M 0.49M 0.73M 0.01M
Capital lease obligations 0.02M 0.02M 0.05M 0.04M 0.01M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M 0.00M 0.00M 0.00M
Change to liabilities - - - 4.24M 3.69M
Net borrowings 21.00M 30.00M 30.00M 10.00M 30.00M
Total cash from financing activities 26.48M 31.23M 40.03M 10.00M 36.81M
Change to operating activities - - - 0.72M 0.07M
Net income -30.84M -47.05M -41.07M -38.78M -30.53M
Change in cash 2.60M -10.54M 7.07M -21.06M 12.51M
Begin period cash flow 15.12M 25.66M 18.59M 39.65M 27.14M
End period cash flow 17.72M 15.12M 25.66M 18.59M 39.65M
Total cash from operating activities -23.88M -41.77M -32.97M -31.06M -24.31M
Issuance of capital stock 3.23M 0.00M - 0.00M 6.81M
Depreciation 0.05M 0.04M 0.03M 0.03M 0.04M
Dividends paid 0.14M 0.09M 0.12M -0.10M -0.17M
Sale purchase of stock 0.67M 0.84M 0.67M 0.90M -
Other cashflows from financing activities 0.14M 0.09M 10.03M 8.30M 30.17M
Change to netincome - - - 2.72M 2.43M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.61M 2.28M 4.68M 4.97M 3.75M
Stock based compensation 1.66M 2.45M 2.26M 2.87M 2.08M
Other non cash items 4.64M 0.51M 1.13M -0.15M 0.49M
Free cash flow -23.88M -41.77M -32.97M -31.06M -24.31M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
GALT
Galectin Therapeutics Inc
-0.09
2.87%
3.05 - 4.54 - 207.70 -4.04
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-4.02
0.74%
538.60 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
4.28
0.45%
955.47 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
64.70
7.19%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071

678 620 3186

9

Name Title Year Born
Mr. Joel Lewis Pres, CEO & Director 1970
Mr. Jack W. Callicutt CPA, CPA CFO, Treasurer & Corp. Sec. 1967
Dr. Pol F. Boudes M.D., Ph.D. Chief Medical Officer 1957
Robert Tritt Gen. Counsel NA
Ms. Beth Knowles Exec. Assistant & Officer Mang. NA
Mr. Joel Lewis President, CEO & Director 1970
Mr. Jack W. Callicutt CPA CFO, Treasurer & Corporate Secretary 1967
Robert Tritt General Counsel NA
Mr. Jeff Katstra Head of CMC & Pharmaceutical Development NA
Ms. Beth Knowles Executive Assistant & Officer Manager NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…